Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: The STAR 3 experience

John B. Buse, George Dailey, Andrew A. Ahmann, Richard M. Bergenstal, Jennifer B. Green, Tim Peoples, Robert J. Tanenberg, Qingqing Yang

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Background: Baseline characteristics from the adult cohort of a randomized controlled trial comparing sensor-augmented pump (SAP) and multiple daily injection (MDI) therapy were analyzed for significant relationships with -0.5% A1C change at 1 year of therapy without incidence of severe hypoglycemia (defined as A1C benefit). Methods: Baseline characteristics were compared with A1C benefit. Statistically significant predictors were analyzed further to determine appropriate cutpoints of relative A1C benefit. Results: Baseline A1C ≥9.1%, age at randomization ≥36 years, and age at diabetes diagnosis of ≥17 years were associated with a greater SAP benefit relative to MDI than other cutpoints. Conclusions: People with type 1 diabetes who had a high A1C and who were older at diagnosis and older at randomization experienced the most benefit from SAP therapy.

Original languageEnglish (US)
Pages (from-to)601-606
Number of pages6
JournalDiabetes Technology and Therapeutics
Volume13
Issue number6
DOIs
StatePublished - Jun 1 2011

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: The STAR 3 experience'. Together they form a unique fingerprint.

  • Cite this

    Buse, J. B., Dailey, G., Ahmann, A. A., Bergenstal, R. M., Green, J. B., Peoples, T., Tanenberg, R. J., & Yang, Q. (2011). Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: The STAR 3 experience. Diabetes Technology and Therapeutics, 13(6), 601-606. https://doi.org/10.1089/dia.2010.0225